메뉴 건너뛰기




Volumn 28, Issue 1, 2014, Pages

Treatment of metastatic pancreatic adenocarcinoma: A review

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN RECEPTOR; BILIRUBIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEONECTIN; OXALIPLATIN; PACLITAXEL; PEMETREXED;

EID: 84893343872     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (113)

References (31)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • Atlanta: American Cancer Society, Inc
    • Cancer Facts & Figures 2013. Atlanta: American Cancer Society, Inc; 2013.
    • (2013) Cancer Facts & Figures 2013.
  • 2
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    • Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
    • (1997) J Clin Oncol. , vol.15 , pp. 2403-2413
    • Burris III, H.A.1    Moore, M.J.2    Andersen, J.3
  • 3
    • 34249933404 scopus 로고    scopus 로고
    • Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    • Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
    • (2007) J Clin Oncol. , vol.25 , pp. 1960-1966
    • Moore, M.J.1    Goldstein, D.2    Hamm, J.3
  • 4
    • 79955921754 scopus 로고    scopus 로고
    • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    • Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25.
    • (2011) N Engl J Med. , vol.364 , pp. 1817-1825
    • Conroy, T.1    Desseigne, F.2    Ychou, M.3
  • 5
    • 84886741654 scopus 로고    scopus 로고
    • Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
    • Von Hoff D, Ervin T, Arena F, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.
    • (2013) N Engl J Med. , vol.369 , pp. 1691-1703
    • Von Hoff, D.1    Ervin, T.2    Arena, F.3
  • 6
    • 37549072095 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. Pancreatic adenocarcinoma, v.1.2013
    • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma, v.1.2013.
    • NCCN clinical practice guidelines in oncology
  • 7
    • 68949114505 scopus 로고    scopus 로고
    • Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group
    • Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-85.
    • (2009) J Clin Oncol. , vol.27 , pp. 3778-3785
    • Poplin, E.1    Feng, Y.2    Berlin, J.3
  • 8
    • 73949135518 scopus 로고    scopus 로고
    • Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
    • Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
    • (2009) J Clin Oncol. , vol.27 , pp. 5513-5518
    • Cunningham, D.1    Chau, I.2    Stocken, D.D.3
  • 9
    • 77950498286 scopus 로고    scopus 로고
    • Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study
    • Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-51.
    • (2010) J Clin Oncol. , vol.28 , pp. 1645-1651
    • Colucci, G.1    Labianca, R.2    Di Costanzo, F.3
  • 10
    • 50849115450 scopus 로고    scopus 로고
    • Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study
    • Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592-9.
    • (2008) Ann Oncol. , vol.19 , pp. 1592-1599
    • Chauffert, B.1    Mornex, F.2    Bonnetain, F.3
  • 11
    • 33748297529 scopus 로고    scopus 로고
    • A multicenter phase III trial comparing irinotecan, gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    • Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan, gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006;95:587-92.
    • (2006) Br J Cancer. , vol.95 , pp. 587-592
    • Stathopoulos, G.P.1    Syrigos, K.2    Aravantinos, G.3
  • 12
    • 27144530079 scopus 로고    scopus 로고
    • A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    • Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-45.
    • (2005) Ann Oncol. , vol.16 , pp. 1639-1645
    • Oettle, H.1    Richards, D.2    Ramanathan, R.K.3
  • 13
    • 4644327989 scopus 로고    scopus 로고
    • Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    • Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-83.
    • (2004) J Clin Oncol. , vol.22 , pp. 3776-3783
    • Rocha Lima, C.M.1    Green, M.R.2    Rotche, R.3
  • 14
    • 77955914277 scopus 로고    scopus 로고
    • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    • Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-10.
    • (2010) J Clin Oncol. , vol.28 , pp. 3605-3610
    • Philip, P.A.1    Benedetti, J.2    Corless, C.L.3
  • 15
    • 35348915953 scopus 로고    scopus 로고
    • Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
    • Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007;25:4506-7.
    • (2007) J Clin Oncol. , vol.25 , pp. 4506-4507
    • Miksad, R.A.1    Schnipper, L.2    Goldstein, M.3
  • 16
    • 36348999029 scopus 로고    scopus 로고
    • Is it cost effective to add erlotinib to gemcitabine in advanced pancreatic cancer?
    • [abstract 6048]
    • Grubbs B, Grusenmeyer PA, Petrelli NJ, et al. Is it cost effective to add erlotinib to gemcitabine in advanced pancreatic cancer? [abstract 6048] J Clin Oncol. 2006;24(suppl 18S):313.
    • (2006) J Clin Oncol. , vol.24 , Issue.SUPPL. 18S , pp. 313
    • Grubbs, B.1    Grusenmeyer, P.A.2    Petrelli, N.J.3
  • 17
    • 84875993686 scopus 로고    scopus 로고
    • Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals
    • Miyabayashi K, Ijichi H, Mohri D, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013;73:2221-34.
    • (2013) Cancer Res. , vol.73 , pp. 2221-2234
    • Miyabayashi, K.1    Ijichi, H.2    Mohri, D.3
  • 18
    • 0042284883 scopus 로고    scopus 로고
    • SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions
    • Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30.
    • (2003) Oncogene. , vol.22 , pp. 5021-5030
    • Sato, N.1    Fukushima, N.2    Maehara, N.3
  • 19
    • 33846916208 scopus 로고    scopus 로고
    • Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma
    • Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-25.
    • (2007) J Clin Oncol. , vol.25 , pp. 319-325
    • Infante, J.R.1    Matsubayashi, H.2    Sato, N.3
  • 20
    • 55949136282 scopus 로고    scopus 로고
    • SPARC in cancer biology: Its role in cancer progression and potential for therapy
    • Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008;11:231-46.
    • (2008) Drug Resist Updat. , vol.11 , pp. 231-246
    • Tai, I.T.1    Tang, M.J.2
  • 21
    • 33748459642 scopus 로고    scopus 로고
    • Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma
    • Gebbia N, Gebbia V. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur J Cancer. 1996;32A:1822-3.
    • (1996) Eur J Cancer. , vol.32 A , pp. 1822-1823
    • Gebbia, N.1    Gebbia, V.2
  • 22
    • 32944482677 scopus 로고    scopus 로고
    • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    • Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-803.
    • (2005) J Clin Oncol. , vol.23 , pp. 7794-7803
    • Gradishar, W.J.1    Tjulandin, S.2    Davidson, N.3
  • 23
    • 0037499918 scopus 로고    scopus 로고
    • Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy
    • Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res. 2003;9:2335-41.
    • (2003) Clin Cancer Res. , vol.9 , pp. 2335-2341
    • Schmitt-Sody, M.1    Strieth, S.2    Krasnici, S.3
  • 24
    • 2542559832 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
    • Kim T-Y, Kim D-W, Chung J-Y, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708-16.
    • (2004) Clin Cancer Res. , vol.10 , pp. 3708-3716
    • Kim, T.-Y.1    Kim, D.-W.2    Chung, J.-Y.3
  • 25
    • 0042284883 scopus 로고    scopus 로고
    • SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions
    • Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30.
    • (2003) Oncogene. , vol.22 , pp. 5021-5030
    • Sato, N.1    Fukushima, N.2    Maehara, N.3
  • 26
    • 33644753906 scopus 로고    scopus 로고
    • Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel
    • Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317-24.
    • (2006) Clin Cancer Res. , vol.12 , pp. 1317-1324
    • Desai, N.1    Trieu, V.2    Yao, Z.3
  • 27
    • 77952168147 scopus 로고    scopus 로고
    • Targeted delivery for breast cancer therapy: The history of nanoparticle-albumin-bound paclitaxel
    • Petrelli F, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother. 2010;11:1413-32.
    • (2010) Expert Opin Pharmacother. , vol.11 , pp. 1413-1432
    • Petrelli, F.1    Borgonovo, K.2    Barni, S.3
  • 28
    • 84893420940 scopus 로고    scopus 로고
    • Approves a drug for late-stage pancreatic cancer
    • Sep 6. Available at
    • Pollack A. F.D.A. approves a drug for late-stage pancreatic cancer. New York Times. 2013 Sep 6. Available at: http://www.nytimes.com/2013/09/07/business/fda-approves-drug-for-late-stage-pancreatic-cancer.ht ml.
    • (2013) New York Times.
    • Pollack, A.F.D.A.1
  • 29
    • 83355169753 scopus 로고    scopus 로고
    • Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial
    • Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-54.
    • (2011) J Clin Oncol. , vol.29 , pp. 4548-4554
    • Von Hoff, D.D.1    Ramanathan, R.K.2    Borad, M.J.3
  • 30
    • 84863849090 scopus 로고    scopus 로고
    • Nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer
    • Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-9.
    • (2012) Cancer Discov. , vol.2 , pp. 260-269
    • Frese, K.K.1    Neesse, A.2    Cook, N.3
  • 31
    • 84875890529 scopus 로고    scopus 로고
    • Cost-effectiveness of systemic therapies for metastatic pancreatic cancer
    • Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20:e90-e106.
    • (2013) Curr Oncol. , vol.20
    • Tam, V.C.1    Ko, Y.J.2    Mittmann, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.